Gara Jalqabaatti › Saree Oljoo › Connecticut › New Haven
Qorannoo klinikaalii Saree Oljoo New Haven, CT keessatti
Qorannoo 37 Saree Oljoo f New Haven fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Namoota walitti qabaa jiraSadarkaa 1/2
- Yale Cancer Center, New Haven
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 2
- Yale Cancer Center, New Haven
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Yale University School of Medicine - Yale Cancer Center, New Haven
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Namoota walitti qabaa jiraSadarkaa 1/2
- Yale University School of Medicine, New Haven
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Yale University - Yale University School of Medicine, New Haven
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Yale Cancer Center, New Haven
Study of AVZO-021 in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Avenzo Therapeutics Recruiting Site, New Haven
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Yale Cancer Center, New Haven
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Namoota walitti qabaa jiraSadarkaa 3
- Yale Cancer Center ( Site 0060), New Haven
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Namoota walitti qabaa jiraSadarkaa 3
- Smilow Cancer Hospital - Yale New Haven Health, New Haven
- Yale University/Yale Cancer Center/Yale School of Medicine, New Haven
- Smilow Cancer Hospital Care Center - North Haven, North Haven · Miili 7 fagaatti
- fi 2 dabalataa
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, New Haven
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Clinical Trial Site, New Haven
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Namoota walitti qabaa jira
- Yale Cancer Center, New Haven
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Yale University School Of Medicine, New Haven
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Namoota walitti qabaa jiraSadarkaa 2
- Yale Cancer Center Clinical Trials Office, New Haven
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Namoota walitti qabaa jiraSadarkaa 3
- Yale New Haven Hospital- Yale Cancer Center, New Haven
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Namoota walitti qabaa jiraSadarkaa 1/2
- Yale Cancer Center, New Haven
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Yale-New Haven Hospital-Yale Cancer Center, New Haven
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Namoota walitti qabaa jiraSadarkaa 3
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · Miili 7 fagaatti
- Smilow Cancer Hospital-Derby Care Center, Derby · Miili 8 fagaatti
- fi 1 dabalataa
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Namoota walitti qabaa jiraSadarkaa 3
- Smilow Cancer Hospital at Yale New Haven, New Haven
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Yale Cancer Center, New Haven
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Namoota walitti qabaa jiraSadarkaa 2
- Yale University Cancer Center, New Haven
Optimizing Surgical Decisions in Young Adults With Breast Cancer
Namoota walitti qabaa jira
- Yale Cancer Center, New Haven
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Namoota walitti qabaa jiraSadarkaa 2
- Yale Cancer Center at Yale University School of Medicine, New Haven
- Smilow Cancer Hospital Care center at North Haven, North Haven · Miili 7 fagaatti
- Smilow Cancer Hospital Care center at Derby, Derby · Miili 8 fagaatti
- fi 1 dabalataa
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Namoota walitti qabaa jiraSadarkaa 3
- Yale Cancer Center - Smilow Cancer Hospital, New Haven
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
Namoota walitti qabaa jiraSadarkaa 3
- Yale University, New Haven
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Yale University, Yale Cancer Center, New Haven
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy
Namoota walitti qabaa jiraSadarkaa 1
- Yale Cancer Center Smilow Cancer Hospital, New Haven
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
Namoota walitti qabaa jiraQorannoo ilaalaa
- Yale Cancer Center, New Haven
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Namoota walitti qabaa jiraSadarkaa 3
- Smilow Cancer Hospital - Yale New Haven Health, New Haven
- Smilow Cancer Hospital - North Haven, North Haven · Miili 7 fagaatti
- Smilow Cancer Hospital - Derby, Derby · Miili 8 fagaatti
- fi 1 dabalataa
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Yale Cancer Center, New Haven
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Namoota walitti qabaa jiraSadarkaa 3
- Yale-New Haven Hospital Saint Raphael Campus, New Haven
- Yale University, New Haven
- Smilow Cancer Hospital-Orange Care Center, Orange · Miili 5 fagaatti
- fi 4 dabalataa
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Yale University, Yale Cancer Center, New Haven
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
Namoota walitti qabaa jira
- Yale University, New Haven
DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY
Namoota walitti qabaa jiraSadarkaa 2
- Yale University, New Haven
The Cancer of the Pancreas Screening-5 CAPS5)Study
Namoota walitti qabaa jiraSadarkaa 3
- Yale University, New Haven
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Yale University, New Haven
Qorannoo Saree Oljoo magaalota biroo keessatti
- New York City, NYQorannoo 134
- Houston, TXQorannoo 126
- Boston, MAQorannoo 111
- Nashville, TNQorannoo 80
- Los Angeles, CAQorannoo 72
- Edison, NJQorannoo 68
- St. Louis, MOQorannoo 64
- Durham, NCQorannoo 63
- Queens, NYQorannoo 63
- Chicago, ILQorannoo 58
- Philadelphia, PAQorannoo 56
- Dallas, TXQorannoo 55
Qorannoo biroo New Haven keessatti
- Kansara Qara'a Non-Small CellQorannoo 41
- Saree (Gosoota Hunda)Qorannoo 33
- Kansara MetastatikiiQorannoo 23
- Dhibee QaraQorannoo 22
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 22
- Kansarii OvariiQorannoo 21
- Kansarii ColorectalQorannoo 20
- Kansarii ProstateQorannoo 20
- Overdose OpioidQorannoo 18
- Alcohol Use Disorder (AUD)Qorannoo 17
- Leukemia Myeloidii HamaaQorannoo 17
- Kansarii PancreasQorannoo 16
Kanneen ClinicalTrials.gov irraa argaman, daataa 05-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.